StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the stock. Separately, Roth Mkm reaffirmed a buy rating and set a $40.00 price target on shares of Bio-Path in a research report on Thursday, April 18th. […]